Who
P. Kent Hawryluk
President & CEO
Company insider
Files Form 4 as: President & CEO, MBX Biosciences; Director, MetaVia.
In numbers
- Trades disclosed
- 35
- Buys
- 5
- Sells
- 1
- Bought
- $2.3M
- Sold
- $36K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 4 Aug 2016
- Last trade
- 6 May 2026
- Last filed
- 8 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 May 2026filed 8 May 2026 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Sold | $18K607 at $29.54 | filing |
| 6 May 2026filed 8 May 2026 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Sold | $18K607 at $29.54 | filing |
| 13 Mar 2026filed 16 Mar 2026 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Bought | $526K18,500 at $28.41 | filing |
| 13 Mar 2026filed 16 Mar 2026 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Bought | $526K18,500 at $28.41 | filing |
| 26 Feb 2026filed 27 Feb 2026 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Code M | $460K28,768 at $16.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —28,768 at $0.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —28,768 at $0.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Code M | $460K28,768 at $16.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Code A | —35,250 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —164,500 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —164,500 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Code A | —35,250 at $0.00 | filing |
| 24 Oct 2025filed 28 Oct 2025 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —182,859 at $0.00 | filing |
| 24 Oct 2025filed 28 Oct 2025 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Code M | $594K182,859 at $3.25 | filing |
| 20 Oct 2025filed 21 Oct 2025 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Bought | $273K20,000 at $13.64 | filing |
| 4 Feb 2025filed 5 Feb 2025 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Bought | $535K50,000 at $10.69 | filing |
| 3 Feb 2025filed 5 Feb 2025 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —243,000 at $0.00 | filing |
| 16 Sep 2024filed 17 Sep 2024 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code C | —2,015,681 | filing |
| 16 Sep 2024filed 17 Sep 2024 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code C | —345,705 | filing |
| 16 Sep 2024filed 17 Sep 2024 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,396,762 | filing |
News
No headline names them, or the companies they trade most, lately.